Interleukin-6 Blockade as Rescue Therapy in Autoimmune Encephalitis

Neurotherapeutics

Volumn 13, Issue 4, 2016, Pages 821-823

  Dale, Russell C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; CXCL13 CHEMOKINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; RITUXIMAB; TOCILIZUMAB; INTERLEUKIN 6;

ALLERGIC ENCEPHALITIS; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; COHORT ANALYSIS; DISEASE SEVERITY; DRUG SAFETY; EDITORIAL; FOLLOW UP; FUNCTIONAL DISEASE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; ENCEPHALITIS; HASHIMOTO DISEASE;

ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; ENCEPHALITIS; HASHIMOTO DISEASE; HUMANS; INTERLEUKIN-6; RITUXIMAB;

EID: 84982161810     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-016-0471-1     Document Type: Editorial

References (14)

1. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391-404.
2. Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother 2015;15:1391-419.
3. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157-65.
4. Byrne S, Walsh C, Hacohen Y, et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflamm 2015;2:e130.
5. Tatencloux S, Chretien P, Rogemond V, Honnorat J, Tardieu M, Deiva K. Intrathecal treatment of anti-N-Methyl-D-aspartate receptor encephalitis in children. Dev Med Child Neurol 2015;57:95-9.
6. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014;83:142-50.
7. Lee WJ, Lee ST, Moon J, et al. Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. Neurotherapeutics 2016. doi:10.1007/s13311-016-0442-6.
8. Kothur K, Wienholt L, Brilot F, Dale RC. CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: A systematic review. Cytokine 2016;77:227-37.
9. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 2014;82:1302-6.
10. Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 2014;24:83-97.
11. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011;108:3701-6.
12. Byun JI, Lee ST, Moon J, et al. Distinct intrathecal interleukin-17/interleukin-6 activation in anti-N-methyl-d-aspartate receptor encephalitis. J Neuroimmunol 2016;297:141-7.
13. Ygberg S, Fowler A, Wickstrom R. Cytokine and Chemokine Expression in CSF May Differentiate Viral and Autoimmune NMDAR Encephalitis in Children. J Child Neurol 2016.
14. Leypoldt F, Hoftberger R, Titulaer MJ, et al. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response. JAMA Neurol 2015;72:180-6.